Cancer

Philadelphia Jury Awards $78 Million in Verdict Against Monsanto for Man’s Cancer Claim Linked to Roundup Usage

by

Philadelphia, PA — A Philadelphia jury held Monsanto liable for $78 million on Thursday, citing that the company’s prominent herbicide, Roundup, played a crucial role in causing a local man’s blood cancer. This significant verdict adds to the growing number of legal challenges facing the agricultural behemoth over the safety of its product. William Melissen, 51, who has used Roundup since 1992, was diagnosed with non-Hodgkin’s lymphoma in 2020. Alongside his wife, Margaret, Melissen initiated a lawsuit against Monsanto and its parent company, Bayer, a German conglomerate, claiming that his prolonged exposure to the herbicide’s … Read more

GSK Settles U.S. Zantac Cancer Claims for $2.2 Billion, Boosting Stock by 6%

by

London – GSK’s stock soared by 6% on Thursday following the announcement that the British pharmaceutical giant has agreed to a multi-billion dollar settlement over allegations that its now-discontinued heartburn medication, Zantac, was carcinogenic. The company will pay up to $2.2 billion to resolve almost all the pending lawsuits in the United States, which is significantly lower than some financial analysts had anticipated. Previously, forecasts by entities such as JP Morgan had estimated potential liabilities to be as high as $3.5 billion. However, the settlement disclosed on Wednesday accounts for about 80,000 cases—or 93%—of the … Read more

Delaware Supreme Court to Review Key Legal Challenges in Massive Zantac Cancer Case

by

Dover, Delaware — Home to more than two-thirds of Fortune 500 companies, Delaware is a beacon of corporate incorporation. The state’s reputation as a legal hub for business is now under the spotlight as the Delaware Supreme Court considers a pivotal appeal that could redefine its approach to mass-tort litigation. Delaware recently came to the forefront of legal discussions due to a substantial case involving over 75,000 plaintiffs. These individuals allege that ranitidine, often sold under the brand name Zantac, is carcinogenic. They argue that the drug breaks down into N-nitrosodimethylamine (NDMA), a substance believed … Read more

$400 Million Victory: Louisiana Jury Holds Major Insurer Accountable for Underpayment in Landmark Case Involving Cancer Patient Care

by

New Orleans, LA — A Louisiana civil court verdict has ordered the state’s premier health insurer, Blue Cross Blue Shield of Louisiana (BCBS), to compensate a surgical hospital over $400 million for a backlog of underpaid claims. This ruling comes as a significant breakthrough for healthcare providers in their ongoing struggle against powerful insurance firms over fair payment practices. The target of the litigation, St Charles Surgical Hospital, known for specializing in cancer treatments, accused BCBS of insufficiently compensating for 9,000 previously authorized procedures over a decade. According to hospital officials, the insurance giant either … Read more